Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds ...

Analyst Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report) and decreased the price target to $50.00 from $55.00. Don't Miss our Black Friday Offers: Unlock your ...

Shares of Moderna Inc. (NASDAQ: MRNA) are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to ...

Trump said during a rally in late October that he would let Kennedy “go wild” on healthcare in the country, and vaccine ...

CNBC's Jim Cramer reports on the latest news regarding Moderna.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...

Coegi used more than 500 million impressions and paid social optimized with attention and emotion metrics to drive 24% of ...

Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.

The Make America Healthy Again PAC is celebrating Kennedy Jr.’s nomination by President-elect Trump to run the HHS. Vaccine ...